Related Experiment Videos
Acute phase reactant proteins as prognostic indicators in cancer.
1Unit for Cancer Research, University of Leeds, U.K.
The Tokai Journal of Experimental and Clinical Medicine
|December 1, 1988
Summary
Elevated levels of acute-phase reactant proteins (APRPs) at cancer diagnosis indicate poor patient survival. Combining APRPs with clinical factors like stage improves their prognostic value for predicting short-term survival risks.
Area of Science:
- Oncology
- Biomarkers
- Cancer Prognostics
Background:
- Acute-phase reactant proteins (APRPs) are systemic markers of inflammation.
- Elevated APRPs are frequently observed in cancer patients.
Purpose of the Study:
- To evaluate the prognostic significance of pre-treatment APRP levels in cancer patients.
- To determine the utility of APRPs as standalone and combined prognostic indicators.
Main Methods:
- Analysis of pre-treatment APRP levels in a cohort of cancer patients.
- Correlation of APRP levels with patient survival data.
- Comparison of APRP utility with established prognostic indices (e.g., tumor stage, performance status).
Main Results:
- Raised pre-treatment APRP levels are associated with unfavorable patient survival.
- APRPs effectively predict shorter-term survival risks, particularly up to 18 months.
- APRP levels often increase in the final 6 months of life, especially in disseminated cancer or sepsis.
Conclusions:
- Pre-treatment APRP levels serve as valuable prognostic indicators in cancer.
- Combining APRPs with clinical staging and performance status enhances their predictive power.
- APRPs may indicate heightened risk during acute events like sepsis in advanced cancer.